8.99
Fulcrum Therapeutics Inc stock is traded at $8.99, with a volume of 365.94K.
It is down -3.23% in the last 24 hours and up +22.81% over the past month.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
See More
Previous Close:
$9.29
Open:
$9.15
24h Volume:
365.94K
Relative Volume:
0.59
Market Cap:
$486.28M
Revenue:
$2.81M
Net Income/Loss:
$-97.34M
P/E Ratio:
-5.6899
EPS:
-1.58
Net Cash Flow:
$-91.47M
1W Performance:
+0.00%
1M Performance:
+22.81%
6M Performance:
+173.25%
1Y Performance:
+153.24%
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
FULC
Fulcrum Therapeutics Inc
|
8.99 | 502.51M | 2.81M | -97.34M | -91.47M | -1.58 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-29-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
May-23-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
May-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Sep-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
Sep-12-24 | Downgrade | BofA Securities | Neutral → Underperform |
Sep-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Sep-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
Sep-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Sep-12-24 | Downgrade | Stifel | Buy → Hold |
Sep-09-24 | Upgrade | BofA Securities | Underperform → Neutral |
May-20-24 | Initiated | Cantor Fitzgerald | Overweight |
Mar-13-24 | Initiated | RBC Capital Mkts | Outperform |
Sep-25-23 | Initiated | Goldman | Neutral |
Aug-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
Aug-22-23 | Upgrade | Stifel | Hold → Buy |
May-04-23 | Downgrade | Goldman | Buy → Neutral |
Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mar-09-23 | Downgrade | Stifel | Buy → Hold |
Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
Nov-15-22 | Initiated | Goldman | Buy |
Mar-08-22 | Initiated | Oppenheimer | Outperform |
Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Mar-22-21 | Initiated | Credit Suisse | Outperform |
Mar-02-21 | Initiated | Stifel | Buy |
Oct-16-20 | Initiated | Piper Sandler | Overweight |
Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
Jun-17-20 | Initiated | BTIG Research | Buy |
Oct-03-19 | Initiated | H.C. Wainwright | Buy |
Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
How to track smart money flows in Fulcrum Therapeutics Inc.Earnings Risk Summary & High Accuracy Buy Signal Tips - newser.com
What drives Fulcrum Therapeutics Inc stock priceShort Selling Opportunities & Low Cost Market Tips - earlytimes.in
How supply chain issues affect Fulcrum Therapeutics Inc. stock2025 Breakouts & Breakdowns & Safe Capital Growth Plans - Trung tâm Dự báo KTTV quốc gia
How to monitor Fulcrum Therapeutics Inc. with trend dashboardsJuly 2025 Sector Moves & Growth Focused Entry Reports - newser.com
How Fulcrum Therapeutics Inc. stock reacts to Fed rate cuts2025 Biggest Moves & Safe Entry Zone Identification - Trung tâm Dự báo KTTV quốc gia
Will Fulcrum Therapeutics Inc. stock outperform value stocksJuly 2025 Fed Impact & Low Risk High Reward Trade Ideas - Trung tâm Dự báo KTTV quốc gia
Can momentum traders help lift Fulcrum Therapeutics Inc.July 2025 Drop Watch & High Return Trade Opportunity Guides - newser.com
Real time alert setup for Fulcrum Therapeutics Inc. performance2025 Valuation Update & AI Based Buy and Sell Signals - newser.com
How institutional buying supports Fulcrum Therapeutics Inc. stock2025 Analyst Calls & Safe Entry Point Identification - newser.com
Fulcrum Therapeutics Inc. stock volume spike explained2025 Dividend Review & Risk Controlled Daily Trade Plans - newser.com
What risks investors should watch in Fulcrum Therapeutics Inc. stockRate Hike & Reliable Price Breakout Signals - newser.com
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 - The Manila Times
Fulcrum Therapeutics Presents Preclinical Data for FTX-6274 as a Potential Treatment for Castration-Resistant Prostate Cancer - Quiver Quantitative
Pattern recognition hints at Fulcrum Therapeutics Inc. upsideJuly 2025 Analyst Calls & Daily Stock Trend Watchlist - newser.com
FTX-6274 Poster 2504P: Fulcrum Shows Preclinical Efficacy in CRPC at ESMO Congress Oct 18, 2025 - Stock Titan
Fulcrum Therapeutics Inc. stock outlook for YEAR2025 Technical Overview & Fast Momentum Stock Entry Tips - newser.com
Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.60 - Defense World
Is Fulcrum Therapeutics Inc. stock poised for growthTrend Reversal & Low Risk Entry Point Guides - newser.com
How to build a dashboard for Fulcrum Therapeutics Inc. stock2025 Short Interest & Reliable Price Action Trade Plans - newser.com
What data driven models say about Fulcrum Therapeutics Inc.’s futureWeekly Stock Analysis & AI Driven Stock Movement Reports - newser.com
What is Leerink Partnrs' Estimate for FULC FY2027 Earnings? - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Leerink Partnrs Has Negative Outlook of FULC FY2027 Earnings - Defense World
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq - MSN
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Oklahoma City NewsThe Oklahoman - FinancialContent
Detecting price anomalies in Fulcrum Therapeutics Inc. with AIIPO Watch & Low Drawdown Investment Strategies - newser.com
What moving averages say about Fulcrum Therapeutics Inc.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
Order flow analysis tools used on Fulcrum Therapeutics Inc.2025 Short Interest & Daily Profit Focused Screening - newser.com
Can Fulcrum Therapeutics Inc. recover in the next quarterProduct Launch & High Return Stock Watch Alerts - newser.com
Fulcrum Therapeutics Inc. stock momentum explainedQuarterly Profit Report & Fast Gain Swing Trade Alerts - newser.com
Fulcrum Therapeutics (NASDAQ:FULC) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Fulcrum Therapeutics (NASDAQ:FULC) Reaches New 12-Month HighHere's What Happened - MarketBeat
Fulcrum Therapeutics, Inc. $FULC Shares Sold by Matisse Capital - MarketBeat
What does recent volatility data suggest for Fulcrum Therapeutics Inc.July 2025 Trends & Community Consensus Picks - newser.com
Technical analysis overview for Fulcrum Therapeutics Inc. stockTrade Ideas & Growth Focused Entry Reports - newser.com
Published on: 2025-10-05 20:19:33 - newser.com
Is Fulcrum Therapeutics Inc. stock trading near support levelsRate Cut & Safe Capital Growth Stock Tips - newser.com
Using flow based indicators on Fulcrum Therapeutics Inc.Trade Entry Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Fulcrum Therapeutics Inc. recovery potential after sell offInflation Watch & Safe Entry Point Identification - newser.com
What earnings revisions data tells us about Fulcrum Therapeutics Inc.Weekly Stock Report & Fast Moving Stock Watchlists - newser.com
Can Fulcrum Therapeutics Inc. stock sustain market leadershipJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - newser.com
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):